Indivior PLC (INVVY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Indivior PLC (INVVY) trades at $21.85 with AI Score 47/100 (Grade C). Indivior PLC develops, manufactures, and sells buprenorphine-based prescription drugs for opioid dependence and co-occurring disorders. Market cap: $3.01B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for INVVY: INVVY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INVVY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INVVY: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Indivior PLC (INVVY) Healthcare & Pipeline Overview
Indivior PLC specializes in buprenorphine-based treatments for opioid dependence and related disorders, marketing SUBLOCADE and SUBOXONE. With a $3.01B market cap and a P/E ratio of 18.65, Indivior operates globally in the specialty generic drug manufacturing sector, focusing on addiction and schizophrenia treatments.
What Is the Investment Thesis for INVVY?
Indivior PLC presents a focused investment opportunity within the specialty pharmaceutical sector, driven by its expertise in opioid dependence treatments. With a market capitalization of $3.01B and a profit margin of 16.9%, the company demonstrates financial stability. Key value drivers include the continued adoption of SUBLOCADE and SUBOXONE, as well as potential pipeline developments in addiction and schizophrenia treatments. Upcoming catalysts include further expansion into international markets and potential regulatory approvals for new formulations. However, potential risks include competition from generic alternatives and evolving regulatory landscapes. The company's beta of -0.06 suggests low volatility relative to the market.
Based on FMP financials and quantitative analysis
INVVY Key Highlights
Market Cap of $3.01B indicates a strong presence in the specialty pharmaceutical market.
- P/E Ratio of 18.65 suggests a reasonable valuation compared to earnings.
- Profit Margin of 16.9% demonstrates efficient operations and profitability.
- Gross Margin of 80.3% highlights strong pricing power and cost management.
- Beta of -0.06 indicates low volatility compared to the overall market.
Who Are INVVY's Competitors?
INVVY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASPHF Ascentage Pharma Group International | $4.53 | +0.00% | $1.69B | 51 |
| DUTV Digital Utilities Ventures, Inc. | $0.55 | +3.46% | $1.91B | — |
| GALNF Galenica AG | $115.00 | +0.00% | $5.73B | 46 |
| KARBF Karo Pharma AB (publ) | $5.25 | +0.00% | $1.52B | 46 |
| CAMRF Camurus AB (publ) | $64.00 | +0.00% | $3.81B | 63 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
| ANIP ANI Pharmaceuticals, Inc. | $77.32 | -0.90% | $1.76B | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INVVY's Key Strengths?
Specialized expertise in opioid dependence treatment.
- Established product portfolio with SUBLOCADE and SUBOXONE.
- Global presence in approximately 40 countries.
- Strong gross margin of 80.3%.
What Are INVVY's Weaknesses?
Reliance on buprenorphine-based therapies.
- Exposure to generic competition.
- Dependence on regulatory approvals.
- Potential for product liability claims.
What Could Drive INVVY Stock Higher?
Potential regulatory approvals for new formulations of SUBLOCADE.
- Expansion of SUBLOCADE market share through increased marketing efforts.
- Pipeline development in schizophrenia treatment with potential clinical trial results.
- Geographic expansion into emerging markets with a growing need for addiction treatment.
What Are the Key Risks for INVVY?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Increased competition from generic alternatives to SUBOXONE.
- Evolving regulatory landscape impacting pricing and reimbursement.
- Dependence on buprenorphine-based therapies.
- Product liability claims related to opioid dependence treatments.
What Are the Growth Opportunities for INVVY?
- Expansion of SUBLOCADE Market Share: SUBLOCADE, Indivior's injectable buprenorphine formulation, offers a significant growth opportunity. The market for long-acting opioid dependence treatments is expanding, driven by the convenience and adherence benefits of injectable medications. Increased adoption of SUBLOCADE, particularly among patients seeking a monthly treatment option, could substantially boost Indivior's revenue. This growth is contingent on effective marketing, favorable reimbursement policies, and continued clinical evidence supporting SUBLOCADE's efficacy.
- Pipeline Development in Schizophrenia Treatment: Indivior's pipeline includes potential treatments for schizophrenia, representing a diversification opportunity beyond opioid dependence. The schizophrenia treatment market is substantial, with a significant unmet need for novel therapies. Successful development and commercialization of a schizophrenia medication could significantly expand Indivior's revenue base and market presence. This growth depends on positive clinical trial outcomes and regulatory approvals.
- Geographic Expansion into Emerging Markets: Indivior has the opportunity to expand its geographic footprint into emerging markets with a growing need for addiction treatment. These markets often have less established treatment infrastructure, presenting an opportunity for Indivior to establish a strong presence. Successful expansion requires navigating local regulatory requirements, establishing distribution networks, and adapting marketing strategies to local market conditions. This expansion could contribute significantly to long-term revenue growth.
- Strategic Partnerships and Acquisitions: Indivior can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. Collaborating with other pharmaceutical companies or acquiring complementary businesses could provide access to new technologies, therapeutic areas, or geographic markets. These partnerships could accelerate growth and enhance Indivior's competitive position. Successful partnerships require careful due diligence and alignment of strategic goals.
- Development of Novel Formulations and Delivery Systems: Indivior can invest in the development of novel formulations and delivery systems for its existing medications. This could include developing new extended-release formulations, alternative routes of administration, or combination therapies. These innovations could improve patient adherence, enhance efficacy, and extend the product lifecycle of Indivior's key products. Successful development requires significant investment in research and development and navigating regulatory approval processes.
What Threats Does INVVY Face?
- Evolving regulatory landscape.
- Pricing pressures from payers.
- Competition from alternative therapies.
- Changes in prescribing guidelines.
What Are INVVY's Competitive Advantages?
- Proprietary drug formulations with patent protection.
- Established brand recognition in the addiction treatment market.
- Specialized expertise in buprenorphine-based therapies.
- Regulatory approvals and market exclusivity for key products.
What Does INVVY Do?
Indivior PLC, established in 2014 and headquartered in North Chesterfield, Virginia, is a pharmaceutical company focused on developing, manufacturing, and selling treatments for opioid dependence and co-occurring disorders. The company's core business revolves around buprenorphine-based prescription drugs, addressing the critical need for effective addiction therapies. Indivior's product portfolio includes SUBLOCADE, an injectable formulation for subcutaneous use, and SUBOXONE, available in sublingual film and tablet forms. These medications are designed to help patients manage opioid withdrawal symptoms and reduce cravings. Additionally, Indivior markets legacy products such as Temgesic, Burpex, and Buprenex. Operating in approximately 40 countries, Indivior has a global presence in the addiction treatment market. The company also engages in research collaborations, such as its agreement with Addex Therapeutics Ltd, to explore innovative approaches to treating addiction and related mental health conditions. Indivior's commitment to addressing the opioid crisis positions it as a key player in the healthcare sector, providing essential medications and contributing to the ongoing efforts to combat addiction worldwide.
What Products and Services Does INVVY Offer?
- Develops buprenorphine-based prescription drugs.
- Manufactures medications for opioid dependence.
- Sells treatments for co-occurring disorders.
- Markets SUBLOCADE injection for subcutaneous use.
- Promotes SUBOXONE sublingual film and tablets.
- Sells legacy products like Temgesic and Buprenex.
- Engages in research collaborations for addiction treatment.
How Does INVVY Make Money?
- Develops and patents proprietary drug formulations.
- Manufactures and distributes prescription medications.
- Markets and sells products to healthcare providers and patients.
- Generates revenue through direct sales and partnerships.
What Industry Does INVVY Operate In?
Indivior PLC operates within the specialty pharmaceutical industry, specifically targeting the opioid dependence and addiction treatment market. This market is driven by the ongoing opioid crisis and the increasing demand for effective treatment options. The competitive landscape includes companies developing both branded and generic medications for addiction treatment. Indivior's focus on buprenorphine-based therapies positions it as a key player in this space, with SUBLOCADE and SUBOXONE representing significant revenue streams. The industry is subject to evolving regulatory requirements and pricing pressures, impacting market dynamics and company strategies.
Who Are INVVY's Key Customers?
- Patients with opioid dependence.
- Healthcare providers prescribing addiction treatment.
- Pharmacies dispensing prescription medications.
- Hospitals and treatment centers.
Company Profile
Indivior PLC operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in North Chesterfield, US. The company is led by CEO Mark Crossley. INVVY has traded publicly since 2015.
Indivior PLC (INVVY) Valuation Context
Valued at $3.01B, INVVY is classified as a mid-cap stock. Relative to its peer group, INVVY's quantitative score of 47/100 is roughly in line with the peer average of 52/100.
Key Financial Metrics
Return on assets is 21.0%, showing how much profit it generates from its asset base. INVVY trades at a trailing price-to-earnings ratio of 20.49, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is -3.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.86 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 4.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Indivior PLC's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.80 places it in the grey zone, a middle ground that warrants monitoring.
INVVY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Indivior's future prospects, indicating that key executives believe the company is undervalued.
- Community sentiment has shifted positively as discussions around the effectiveness of Indivior's products have gained traction online.
- The ongoing expansion into new markets has sparked optimism among investors, highlighting growth opportunities beyond traditional regions.
- Recent partnerships and collaborations have bolstered the company's reputation, leading to increased interest from both retail and institutional investors.
Bear Case
- Concerns over regulatory scrutiny have resurfaced, causing apprehension among investors about potential impacts on operations and profitability.
- Social sentiment has shown signs of caution, with some community members expressing doubts about the sustainability of recent growth.
- There are ongoing competitive pressures in the market, with new entrants challenging Indivior's market share and pricing strategies.
- Recent earnings reports have raised questions about revenue consistency, leading to a more bearish outlook among certain analysts and traders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
INVVY Latest News
No recent news available for INVVY.
INVVY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INVVY.
Price Targets
Wall Street price target analysis for INVVY.
INVVY MoonshotScore
What does this score mean?
The MoonshotScore rates INVVY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Mark Crossley
CEO
Mark Crossley serves as the CEO of Indivior PLC, leading a team of 1000 employees. His background includes extensive experience in the pharmaceutical industry, with a focus on commercial strategy and market access. Prior to joining Indivior, Crossley held leadership positions at various pharmaceutical companies, where he oversaw product launches, market expansion, and strategic partnerships. His expertise spans across multiple therapeutic areas, including addiction treatment and mental health. Crossley's experience positions him to drive Indivior's growth and innovation in the addiction treatment market.
Track Record: Under Mark Crossley's leadership, Indivior PLC has focused on expanding the market share of SUBLOCADE and advancing its pipeline of potential treatments for schizophrenia. Key milestones include navigating regulatory challenges and expanding the company's presence in international markets. Crossley has also emphasized strategic partnerships to enhance Indivior's research and development capabilities. His leadership aims to strengthen Indivior's position as a key player in the addiction treatment market.
Indivior PLC ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. For INVVY, as an ADR, it allows U.S. investors to invest in Indivior PLC, a company based in North Chesterfield, US, without the complexities of cross-border transactions. The ADR is denominated in U.S. dollars, simplifying trading and reporting for U.S. investors.
- Home Market Ticker: Primary stock exchange and country: London Stock Exchange, United Kingdom
- ADR Level: 1
- ADR Ratio: 1:1
INVVY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that Indivior PLC (INVVY) may not meet the minimum financial or regulatory requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may be subject to greater risks compared to companies listed on major exchanges like the NYSE or NASDAQ. Trading on the OTC Other tier can result in less liquidity and wider bid-ask spreads.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for lower trading volumes and liquidity.
- Wider bid-ask spreads and price volatility.
- Increased risk of fraud or manipulation.
- Higher potential for delisting or trading suspensions.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC securities.
- Consult with a financial advisor before investing.
- Monitor news and developments related to the company.
- Established operating history in the pharmaceutical industry.
- Presence of branded products like SUBLOCADE and SUBOXONE.
- Global operations in approximately 40 countries.
- Research collaborations with other companies.
Common Questions About INVVY (Healthcare)
What does the AI Score mean for INVVY?
INVVY holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Indivior PLC develops, manufactures, and sells buprenorphine-based prescription drugs for opioid dependence and co-occurring disorders. The company's primary focus is on addressing opioid use …
What does Indivior PLC do?
Indivior PLC is a pharmaceutical company focused on developing, manufacturing, and selling buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. Its primary products include SUBLOCADE, an injectable medication, and SUBOXONE, available in sublingual film and tablet forms. These medications help patients manage opioid withdrawal symptoms and reduce cravings. Indivior operates globally, addressing the critical need for effective addiction therapies.
What are the main risks for INVVY?
The main risks for Indivior PLC include increased competition from generic alternatives to SUBOXONE, evolving regulatory landscapes impacting pricing and reimbursement, and dependence on buprenorphine-based therapies. Additionally, the company faces potential product liability claims related to opioid dependence treatments. Investors should also consider the risks associated with trading on the OTC market, including limited liquidity and disclosure.
What are the key factors to evaluate for INVVY?
Indivior PLC (INVVY) holds an AI score of 47/100 (low). Indivior PLC presents a focused investment opportunity within the specialty pharmaceutical sector, driven by its expertise in opioid dependence treatments. Not financial advice.
How frequently does INVVY data refresh on this page?
INVVY's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven INVVY's recent stock price performance?
Indivior PLC (INVVY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in opioid dependence treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INVVY overvalued or undervalued right now?
Indivior PLC (INVVY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research INVVY before investing?
Before investing in Indivior PLC (INVVY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding INVVY to a portfolio?
Key strength of Indivior PLC (INVVY): Specialized expertise in opioid dependence treatment. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis pending for INVVY, which may provide additional insights.